At present the pathogenesis of pneumonia is not fully discovered, for instance it concerned the role and importance of immune processes alteration in development of pneumonia as well as action of thiotriazolin during pneumonia.
The aim of our research was study of humoral (CD19) and cellular (CD3) immunity on the model of experimental pneumonia (EP) and discovery of thiotriazolin effect on the EP. The research was conducted on guinea pigs. It is shown that on the 10th and 18th days of EP the level T-lymphocytes increased by 76.8 and 78.7% correspondently. While the level of B-lymphocytes increased by 56.3 and 61.2% correspondently; rate f circulating immune complexes in the blood became larger by 62.3 and 81.5% correspondently. Administration of 100 mg/kg of thiotriazolin intramuscularly during 10–18 days of EP has shown an increase of T-lymphocytes level in blood by 35.6% (Р<0.05), a decrease of В-lymphocytes and circulating immune complexes in blood by 39.5 and 41.6% (Р<0,05) correspondently in comparison with untreated animals. The obtained data proved an immune corrective effect of thiotriazolin at the EP. This can be explained by anti-oxidant properties of thiotriazolin.